Case Acceptance Rate Calculator

Only when the current-to-target gap is a relatively small share of the target itself. At the calculator's defaults (60% current, 80% target -- a 20-point gap on an 80% target), a 10% relative increase in the target moves Annual Revenue Gain roughly four times as much as the same 10% increase applied to Cases Presented per Month, since Cases Presented per Month is a simple multiplier while Target Acceptance Rate widens the gap the gain is built from. That amplification shrinks toward 1x -- meaning the two inputs behave about the same -- the wider the starting gap is relative to the target, for example a practice at 5% current chasing a 60% target.

Raising Current Acceptance Rate narrows the gap to the target rather than widening it, which reduces the projected Annual Revenue Gain -- the calculator is measuring the value of closing a performance gap, so improving current performance while holding the target fixed shrinks the opportunity being modeled rather than growing it. In practice this is correct: a practice already closer to its goal has less remaining upside to capture.

Revenue per % Point divides Annual Revenue Gain by the number of percentage points separating Current and Target Acceptance Rate, producing a marginal figure -- how much one additional point of acceptance-rate improvement is worth in dollars. This is useful for comparing the return on a specific initiative, like adding a treatment coordinator or offering in-house financing, against its cost, rather than only seeing the total dollar opportunity across the full gap.

No -- the model assumes every additional accepted case at the target rate is fully staffed, scheduled, and treated without constraint, and it does not check chair availability, doctor capacity, or scheduling limits. A practice modeling a large acceptance-rate improvement should separately confirm it has the operatory and provider capacity to deliver the additional case volume the target rate implies before budgeting around the projected revenue gain.